Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), for intravenous infusion, preservative free, 50 mL Single Dose Bottle, Rx only, Fresenius Kabi Lake Zurich, IL 60047, NDC 63323-671-05

Cross Contamination with other products: trace amounts of lidocaine

Recall #: D-1537-2020
Affected scope: 25,100 bottles
Initiated: July 22, 2020

Compiled from official public sources by the publisher. · Updated September 2026

Fresenius Kabi USA, LLC recalled Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), … - a critical-severity action.

Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), … was recalled by Fresenius Kabi USA, LLC in September 2, 2020. Reason: Cross Contamination with other products: trace amounts of lidocaine. Check the official notice for the remedy. Verify recall #D-1537-2020 with the FDA Drug before acting.

The recall

Fresenius Kabi USA, LLC issued this critical-severity FDA Drug recall-Cross Contamination with other products: trace amounts of lidocaine.

Critical
severity level: Class I
classification: September 2, 2020
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1537-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), for intravenous infusion, preservative free, 50 mL Single Dose Bottle, Rx only, Fresenius Kabi Lake Zurich, IL 60047, NDC 63323-671-05

Reason for recall

Cross Contamination with other products: trace amounts of lidocaine

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Critical (Class I)
Status	Terminated
Recall number	D-1537-2020
Date reported	September 2, 2020
Date initiated	July 22, 2020
Recalling firm	Fresenius Kabi USA, LLC
Firm location	Lake Zurich, IL
Affected scope	25,100 bottles
Distribution	U.S.A. Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1537-2020) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Cross Contamination with other products: trace amounts of lidocaine

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on September 2, 2020. Severity: Critical. Recall number: D-1537-2020.

Where was the recalled product distributed? ▼

Distribution: U.S.A. Nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Critical), closest by report date among other firms and states.

VOLVO 2021: STEERING 2020-09-02 VOLVO 2020-2021: SERVICE BRAKES, AIR 2020-09-02 Chlorhexidine Gluconate 0012 For Manufact… 2020-09-02 Heparin Sodium 2,500 units in 0.9% Sodium… 2020-09-02

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Buprenorphine HCl Injection, 0.3 mg/mL, 1… 2020-09-02 Sulfamethoxazole and Trimethoprim Tablets… 2020-09-02 Hand Sanitizer (Alcohol 80% v/v) topical … 2020-09-02 Rocky Mountain Sunscreen SPF30 Kiwi Flavo… 2020-09-02

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported September 2, 2020. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026